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Abstract
Background: We propose, model, and implement a novel system of population-level intervention against a virus.
One context is a treatment against a chronic infection such as HIV. The underlying principle is a form of virus ‘wars’ in
which a benign, transmissible agent is engineered to protect against infection by and spread of a lethal virus. In our
specific case, the protective agent consists of two entities, a benign virus and a gene therapy vector mobilized by the
benign virus.
Results: Numerical analysis of a mathematical model identified parameter ranges in which adequate,
population-wide protection is achieved. The protective system was implemented and tested using E. coli,
bacteriophage M13 and a phagemid vector mobilized by M13 to block infection by the lethal phage T5. Engineering
of M13 profoundly improved its dynamical properties for facilitating spread of the gene therapy vector. However, the
gene therapy vector converts the host cell to resist T5 too slowly for protection on a time scale appropriate for T5.
Conclusions: Overall, there is a reasonable marriage between the mathematical model and the empirical system,
suggesting that such models can be useful guides to the design of such systems even before the models incorporate
most of the relevant biological details.
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Background
The most successful antiviral defenses are vaccines, work-
ing by blocking infection of the host. Unfortunately, vac-
cines are not available for many types of viral infections.
Drugs are a second form of defense, usually applied after
infection, but drugs commonly work poorly or succumb
to rapid evolution of viral resistance [1]; with HIV, drug
combinations work well at controlling infections but not
curing. A third approach, specific to chronic infections
such as HIV, is to introduce an infectious and replicat-
ing antiviral agent that interferes with the chronic virus in
the same host. By limiting the density of the chronic virus
in the host, symptoms of the infection are weakened and
transmission of the chronic virus to new hosts is reduced.
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The third approach of using one virus to thwart another
within the same host (virus ‘wars’) has its roots with nat-
urally occurring viral parasites known as defective inter-
fering particles (DIPs). DIPs occur in many virus systems.
They evolve to propagate themselves at the expense of
their parent virus (known as a ‘helper’) and thereby offer
a mechanism to suppress density of the parent/chronic
virus [2, 3]. They equally point toward a much wider spec-
trum of interference mechanisms that are now feasible
with genetic engineering. One novel design is to engi-
neer a virus that specifically attacks cells infected with
the chronic virus, killing them and replicating at the same
time [4, 5]. A second design is to use a DIP to interfere
with its ‘helper’ when the helper is the cause of symptoms
[2, 6–8]. In the new method developed here, an engi-
neered DIP and its helper virus are used in combination
to resist infection by a third virus.
All variants of the virus wars approach have in com-
mon the use of one replicating virus to curtail prop-
agation by another virus in the same host. Yet even
with genetic engineering, ultimate success may prove
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challenging, requiring a suitable within-host ‘ecology’ and
engineering exquisitely tailored to that ecology. It is not
enough that the engineering cause the desired interfer-
ence at the cellular level, the engineering must also satisfy
dynamic constraints at the population level [6, 8, 9]. In
these early days of designing such unprecedented interfer-
ence mechanisms, success is likely to involve a continuing
handshake between engineering, modeling, and empirical
efforts. An important but unresolved question is where
the generalities reside: will most of the hurdles lie in
details specific to an application? Or will empirical gen-
eralities emerge that transcend the specific application?
That question underlies the development of our model
system here.
We propose a novel type of intervention against a
chronic viral infection: a two-component system (similar
to a DIP and its parent, helper virus) is engineered to work
together in interfering with a third virus, a lethal virus.
Our study is developed in three stages. First, we introduce
the basic biology of our system. Second, this approximate
biology is used to develop a mathematical model, which
is then analyzed. Third, the biological components are
assembled and their dynamical properties tested for fit to
the model. A particular focus is the extent to which one
can move from superficial biological properties to imple-
mentation. In this respect, our approach should serve as
an example for other systems. The comparison of theo-
retical and empirical dynamics allows us to highlight the
different hurdles thwarting success with the system and to
propose how further engineering might overcome those
hurdles.
A system like the one developed here could be used in
a range of applications: as a transmissible vaccine, as a
therapeutic virus administered to reduce symptoms in a
patient already infected, or as a prophylactic vaccine. Our
analyses do not explore all possible applications; rather
they explore basic dynamics in a way that tests our under-
standing of the system and could thereby be used to
improve various implementations.
Empirical system
A design from established biology
We develop an infectious, two-component gene therapy
system to protect a host cell population against decima-
tion by a lethal virus (the lethal virus is equivalent to the
‘chronic’ virus in our Introduction). The viruses are bacte-
riophages and the ‘host’ is a cell, the bacterium E. coli. The
lethal virus is the lytic bacteriophage T5. The two com-
ponent protection system consists of the non-lethal phage
M13 and a separate, engineered plasmid that genetically
converts the host cell to resist T5. To avoid confusion over
different meanings of ‘host’ that are used in the infec-
tious disease literature, we will henceforth refer to the
bacterium as a ‘cell,’ ‘host cell’ or ‘bacterial host.’
Both elements of the two component system are
needed to protect a population of cells. M13 spreads
autonomously but does not protect its host cell, whereas
the plasmid protects its host cell but cannot spread unless
the cell also carries M13 – the plasmid is designed to
be mobilized by M13. Given these asymmetries, we will
refer to M13 as the ‘helper’ virus and the plasmid as
’vaccine.’
Except for its gene therapy capacity, our two-component
protection system offers a close dynamic parallel to that of
a defective-interfering particle and its autonomous, helper
virus that it parasitizes. In our case, the two-component
system is designed to block a third virus, which sep-
arates our purpose from prior therapeutic applications
of DIPs [2, 6–8]. Empirical details of these viruses and
their host cell are presented below. Some specific prop-
erties are described in Table 1. An asymmetry that is
especially noteworthy is that vaccine-infected cells can be
infected by helper virus, but helper-infected cells cannot
be infected by vaccine.
The Lethal Virus: Bacteriophage T5
Bacteriophage T5 is a lytic phage whose genome is just
over 120kb of dsDNA and encodes up to 168 genes
[10]. It invariably causes a lethal infection of its bac-
terial host, with progeny released when the cell bursts.
For infection, T5 requires the outer membrane receptor
encoded by the bacterial gene fhuA. Knockout of fhuA
renders the bacterium resistant to T5 infection and is
the gene therapy target of our vaccine. As active cells
have ≈ 1000 FhuA molecules per cell [11], resistance to
T5 not only requires the knockout of fhuA but also loss
of existing receptors, which may be achieved by dilu-
tion through cell division. Together, both processes may
result in a substantial delay between vaccine infection and
protection.
Table 1 Cell and virus properties
Type of cell If infected by Outcome
Uninfected Lethal virus Cell dies; lethal virus produces
progeny
" Vaccine Protected against lethal virus;
remains susceptible to helper virus;
cannot produce vaccine progeny
" Helper Remains susceptible to lethal virus;
produces helper progeny; can no
longer be infected by vaccine
Vaccine-
infected
Helper Remains protected against lethal




Lethal virus Cell dies; lethal virus produces
progeny
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The Helper Virus: M13 phage
M13 is a non-lethal bacteriophage that infects F-piliated
E. coli via attachment to the pilus. Its genome is 6407 bases
of circular, single-stranded DNA, that upon infection, is
converted to a dsDNA circle from which state all phage
functions are expressed [12, 13]. Eleven protein coding
genes are recognized, and an intergenic region contains
several regulatory signals and is also suitable for insertion
of cloned sequences.
M13 is atypical of most bacteriophages in that it does
not lyse or kill its bacterial host; it establishes a persistent
infection throughout the life of the host, and the infec-
tion is transmitted to daughter cells when the host divides.
Phage progeny production is via continual secretion of
phage virions through the cell wall andmembranes –most
virion assembly occurs as the genome is extruded through
the membranes. M13 does adversely affect the growth
rate and maximal cell density of the infected bacteria [14],
but these fitness effects are minor in comparison to being
killed (e.g., by T5).
Mobilizable Vaccine: a phagemid engineered to knock out a
bacterial host receptor gene
M13 will process and package other circular genomes
in the same cell if those genomes carry the appropriate
regulatory sequences. Defective interfering particles [15]
and engineered plasmids known as phagemids are pack-
aged. Indeed, DIPs and phagemids act as parasites of M13
because they usurp resources that would otherwise go
toward M13 progeny (see also below).
Our vaccine scaffold is a phagemid, an autonomous
ColE1 plasmid, (ampicillin resistant) engineered to also
carry the M13 origin of replication. When in a cell, the
phagemid can replicate as a plasmid regardless of whether
the cell also carries M13; it is transmitted to daughter
cells. However, the phagemid cannot produce infectious
particles unless the cell also carries M13, because the
phagemid does not encode any of the proteins required for
assembly. If M13 is also in the cell, it packages phagemid
genomes which are then secreted as infectious particles.
TheM13 thatmobilizes the phagemid is denoted a ’helper’
because of its indispensable role in mobilizing transmis-
sion of the phagemid, even though the helper is equally
considered a selfish element being parasitized by the
phagemid.
As with an M13 infection, phagemids infect bacteria
using the F pilus of the cell. As phagemids infect via
the same receptor used by M13, phagemids can only
infect cells that have not been previously infected by M13,
because infection by M13 leads quickly (within 15 min)
to a block of infection by other M13 and related particles.
However, the infection block is not symmetric: infec-
tion by a phagemid does not interfere with subsequent
infection by M13.
We cloned a ‘targetron’ [16] into the phagemid (the con-
struct is henceforth denoted pgT) to act as our vaccine.
Targetrons are programmable group II introns that can
insert into a specified target gene on the bacterial chro-
mosome. pgT was engineered to encode a targetron that
inserts into the E. coli fhuA gene. When pgT infects the
cell, the targetron inserts a copy of itself into the bac-
terial fhuA gene, disrupting its expression and thereby
converting the cell to be genetically resistant to phage T5.
The ability of the targetron to disrupt fhuA was tested by
growing phagemid-infected cells overnight and plating on
ampicillin and T5, which would kill T5-sensitive cells and
kill any cells lacking the phagemid. 10 of 10 colonies were
found by PCR to have the fhuA gene disrupted with an
insert of the correct size. This test informs us that the con-
struct converts cells to resist T5 at a rate higher than the
background mutation rate.
The Bacterial Host: Escherichia coli
We used a lab strain of E. coli (IJ338, see Methods) that
carries the F’ plasmid required by our vaccine helper
phage. This strain also expresses the fhuA gene encoding
the T5 receptor. Cells must be actively growing to allow
for efficient and rapid amplification of phages.
Amathematical model of dynamics
Our empirical system lends itself to mathematical mod-
eling; indeed modeling is required for a full understand-
ing. We have two goals that benefit from mathematical
models. One is to test the predictability of the empirical
dynamics - are the dynamics robust to the many biologi-
cal nuances of the system such that they can be captured
despite the necessary approximations needed for model-
ing? The second goal is to explore dynamical behaviors
that are not easily assayed empirically, perhaps because we
cannot engineer the desired biology; the models can be
a prelude to experimentation to decide which dynamical
behaviors justify empirical testing.
Our system includes four biological entities (cells and
viruses), but there are also five types of infection that
must be considered (Table 4 in Appendix). The four basic
entities are as follows.
(i) Uninfected, susceptible bacterial cells (density Hu).
(ii) A lethal virus (density L) that, if unimpeded, will
spread into the bacterial population and kill most
cells.
(iii) A helper virus (density M) that, by itself, has little
effect on the bacterial host and does not protect the
bacterium from lethal virus infection/killing.
(iv) A phagemid vaccine (density V) that genetically
converts the cell to block infection by the lethal virus;
the phagemid is mobilizable by the helper virus but
can infect only cells that are free of the helper virus.
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The five states of infection accommodate cells infected
with phagemid, with helper, helper plus phagemid, and
whether cells with phagemid have become resistant to the
lethal virus or are still sensitive.
The dynamics of this transmissible vaccine model sys-
tem can be described by a system of differential equations
[Eq. (A1), Appendix], with notation given in Table 4 in
Appendix. These equations are tuned to the specific biol-
ogy of our empirical system. Both the vaccine and helper
elements establish life-long infections of the bacterial host




The equations incorporate 14 parameters. Some of these
can be gleaned to a suitable approximation from the
extensive literature on phage biology, such as adsorption
rates, burst sizes and lysis times of lytic phages [14, 17, 18].
Others, such as reproductive parameters and parameters
specific to our engineering must be estimated as part of
this study, as follows.
Output from infected cells
Critical to the spread of the vaccine is the reproduc-
tive output from cells carrying either the helper alone or
helper plus vaccine (the subscripted b terms in Table 4
in Appendix). Estimation of particle output from infected
cells is partly intuitive (one counts the number of parti-
cles per cell after a fixed time), but is complicated slightly
by the fact that the infected cells are growing during the
time that particles are accumulated. This latter complica-
tion is easily addressed, however (see Methods), and the
procedure also provides an estimate of the growth rate
of the infected cell (r). Table 2 provides estimates for the
engineered helper and the vaccine; the table also provides
parallel estimates for the the wild-type helper and vaccine.
The helper M13 used here (M13KO7) carries a mutation
deliberately chosen to shift progeny in favor of phagemid
over helper. The comparison of helper and wild-type
offers a measure of the efficacy of the engineering.
The estimates are highly variable, no doubt reflecting
many factors that affect cell accommodation of the non-
lethal phage. However, the engineered helper phage has
far more desirable properties than does wild-type – the
output of vaccine relative to helper (bVM : bMV ) is approx-
imately 1:1 for wild-type and 100:1 for engineered (the
benefit of which will be shown below). The engineer-
ing has also been accompanied by a reduction in the
autonomous growth rate of the helper (bM). (Note that the
estimates in Table 2 are per hour to facilitate comprehen-
sion; those in Table 4 in Appendix are per minute.)
Delayed protection
The vaccine can be effective only to the extent it confers
resistance soon after infecting its bacterial host. There are
several steps between infection by a phagemid and resis-
tance to T5. The targetron must first integrate into fhuA
and inactivate its function. Then existing FhuA recep-
tors must decay or be diluted. With 1000 receptors per
cell and no decay of existing FhuA, complete protection
of half the population would require at least 10 genera-
tions after integration (assuming that receptors are equally
distributed across daughters), but substantial levels of
protection would possibly be achieved well before this
time.
The time to vaccine protection against T5 was assayed
in two similar ways. In both, cells were infected with
vaccine and exposed to T5 at later times. In one assay,
vaccine-infected cells were plated onto T5-laden plates at
measured intervals (Fig. 1). In the other assay (Table 3),
the culture was infected with vaccine, grown for several
hours, plated (to measure vaccine-infected cell density)
and then inoculated with T5. At 3-4 hrs after T5 addi-
tion, the culture was plated to measure surviving cells. As
the lethal virus titer (concentration) at plating exceeded
cell concentration by at least 10-fold, nearly all unpro-
tected bacteria will be killed, so the change in density of
vaccine-infected bacteria should be an adequate measure
of protection afforded by the vaccine. In fact, the mea-
sure is an upper bound, because resistant cells were able
to grow after T5 decimated the population.
Both assays allow the same conclusion. Resistance to T5
is slow to be attained, at least on a scale of hours. The
Eqs. (A1) assume that cells infected with vaccine become
T5 resistant at a constant rate; we consider a value of
c = 0.001 (/min) to be a suitable approximation to these
results (an average of 16.7 hr, with half the population
Table 2 Reproductive rates of infected cells (per hr)
Cell r bM bMV bVM
Helper-infected 1.83 ± 0.17 26.2 ± 8.4 - -
Wt-infected 1.56 ± 0.01 106.7 ± 74.8 - -
Doubly-infected
(helper)
1.53 ± 0.03 - 0.34 ± 0.12 43.4 ± 17.3
Doubly-infected
(wt)
0.88 ± 0.16 - 1.2 ± 0.88 1.9 ± 1.47
Entries are means ± standard errors. Original data in Additional file 1

















Fig. 1 Protection against T5 infection provided by the phagemid-
encoded Targetron. Cells were infected by the ampicillin-resistant
phagemid (vaccine) at an MOI of 1.0 (phagemid stock also contained
a low concentration of helper phage at MOI 0.01) and grown for the
time indicated. They were plated separately on ampicillin and on a
high density of T5. The log10 proportion of ampicillin-resistant cells
that are T5-resistant is shown. Resistance levels are never more than
1 % and often not more than 0.1 %, even after 8 h. Colors indicate
replicates; only one sample was assayed at 8 h
becoming resistant in 11.5 hr). For the sake of model anal-
ysis, Table 4 in Appendix also includes a value of c = 0.1
to consider the possible benefits of improved engineering
of this parameter value.
Model dynamics of vaccine and helper virus only
The most pressing question is whether a vaccine that
must be mobilized by a helper virus can spread com-
pletely enough to protect most or all of the population,
Table 3 Population-level vaccine protection against lethal virus
Lag between vaccine and
lethal virus additiona
Fold drop in concentration/titer
of vaccine-infected cells due to
T5 killingb




aCells at 108/mL were infected with vaccine and helper; the vaccine multiplicity of
infection was 1, so infections by vaccine would thus have been nearly complete
within 30 minutes
bCounts to establish the baseline, before T5 addition, were of vaccine-infected
(ampicillin-resistant) cells without specific regard to T5 sensitivity. (For ’no vaccine,’
initial counts are based on total cells.) At 3-4 hr after T5 addition (at the time of
plating), T5 density was at least 10X that of cell density, so nearly all sensitive cells
would have been been unable to form a colony
even in the absence of the lethal virus. If the vaccine can-
not spread well, any protection it affords will necessarily
be minimal. Intuition suggests that the dynamics are not
favorable for vaccine spread in this system: the vaccine
cannot spread by itself and it also cannot infect a cell
already infected with the helper virus, whereas the helper
virus faces neither constraint. Therefore the dynamics
appear to favor the helper virus over the vaccine, an out-
come that would fully undermine the two-component
system. Alternatively if vaccine spread is merely sensitive
to parameter values, then the models may guide efforts to
engineer strains whose biology is compatible with favor-
able dynamics. Indeed, it is well known that DIPS can
vastly out-reproduce their parent (helper) virus at high
density, offering hope that conditions can be identified (or
engineered) that will allow our vaccine to prevail.
Eqs. A1 were numerically solved for bacterial popula-
tions infected with helper virus and vaccine but lacking
the lethal virus. Parameter values were those of Table 4
in Appendix. To offer a sense of dynamics, runs from a
few trials are illustrated in Fig. 2. A comparison of pan-
els shows the effect of the number of initial ’vaccinations’
(bacteria given the vaccine and helper at the outset) as
well as a change in two reproductive parameter values
that match the observed difference between our wild-type
and engineered M13 viruses. Of primary interest is the
fraction of the population infected with vaccine within
a reasonable time frame. Bacteria that are uninfected
may eventually acquire the vaccine, but bacteria that are
infected with helper only are forever susceptible to the
lethal virus. Thus there are two ways the vaccine system
may fail: the vaccine is slow to spread but would eventually
cover most of the population, or the helper outpaces the
vaccine. All but panel (D) uses the approximate estimated
parameter values for the different fecundities (in Table 4
in Appendix), and it is evident that either a large number
of ‘manual’ vaccinations (e.g., 2 %) is needed for ultimate
protection of most of the population, or further improve-
ment in reproductive parameters must be attained. Our
intuition about unfavorable dynamics is therefore correct,
but the problem is potentially correctable in two ways.
A suggestion from Fig. 2 is that vaccine spread may
depend heavily on the reproductive parameters of the vac-
cine and helper, but few values were tried. The problem
is challenging to grasp intuitively because of the multi-
ple effects of helper reproduction: a helper that spreads
rapidly on its own may block vaccine spread, yet helper
spread also indirectly facilitates vaccine spread. A large set
of runs was conducted to explore the sensitivity of out-
comes to three reproductive parameters: (i) autonomous
helper reproduction rate (bM, progeny from a helper-
infected cell, per minute), (ii) vaccine output from a
doubly-infected cell (bVM), and (iii) helper reproduction
rate from a doubly-infected cell (bMV ).
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Fig. 2 Effect of initial vaccinations and reproductive parameters on dynamics of vaccine and helper. All bacteria ultimately become infected with
helper, but protection by vaccine accrues only to the bacteria that (also) receive vaccine. Furthermore, vaccine can only be acquired before a cell is
infected with helper, so cells infected with helper-only can never become protected. Thus we care most about the long term fraction of all cells
infected with vaccine regardless of whether they are also infected with helper (thick dark red). a Using parameters from Table 4 in Appendix, and
introducing only 100 initial vaccinations (as doubly-infected cells at time 0) the vaccine is vastly outpaced by helper by nearly 4 logs and is
ineffective at protecting the population. Progressively higher numbers of initial vaccinations yield progressively better vaccine coverage [(b), (c)].
Panel d increases the reproductive output 10-fold for doubly-infected cells (bVM = 7, bMV = 0.06) but otherwise uses the same conditions as in (b):
there is a substantial improvement in coverage. Both c and d result in most infected cells carrying vaccine. Thus improvement in reproductive
parameters and high levels of ‘manual’ vaccination are different ways to substantially increase coverage. Equations used are given in (A1) with lethal
virus omitted; parameter values were as in Table 4 in Appendix, except as indicated for (D). Initial vaccinations were added as HVMS at time 0
Figure 3 shows the level of vaccine and helper cover-
age at time 400 (6.7 h); results are color-coded to facilitate
comprehension. Areas in purple have the best vaccine per-
formance, yellow (or white) the worst, and it is easily seen
that these parameter values have a huge effect on vaccine
success. By comparing right and left panels, the benefit of
the engineering is seen: engineering gave the vaccine an
almost 100-fold reproductive advantage over helper virus
in the same cell, so the left panels assume the approx-
imate wild-type state of bVM/bMV = 1 and the right
panels assume the engineered state of bVM/bMV = 100.
The purple zone of acceptable vaccine performance is
greatly expanded and is much closer to the engineered
helper-vaccine system (on the right) than it is to wild-type
(on the left). By comparing top to bottom, the figure also
shows the effect of the initial number of vaccinations –
of the the number of doubly-infected cells added at the
outset (100 or 100,000).
There is substantial improvement from increasing the
number of individuals vaccinated at the outset. This ben-
efit of increased ‘manual’ vaccinations likely stems from
the ability of the helper virus but not the vaccine to propa-
gate autonomously and from the vaccine being blocked at
infecting a helper-infected cell. If the number of doubly-
infected cells added to the culture is very low, their vaccine
and helper progeny will tend to infect different cells.
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Fig. 3 Vaccine success rates depend on manual vaccinations and the reproductive properties of vaccine and helper. Each panel shows the results
from hundreds of numerical simulations stopped at time 400. For each combination of bM and bMV tested, the proportion of bacterial hosts with
vaccine over all infected bacteria (at time 400) is indicated with color – purple is best, yellow worst. Color opacity is scaled in proportion to the
fraction of infected bacteria over all bacteria. As most simulations resulted in all or nearly all bacteria becoming infected with either vaccine or
helper by time 400, most of the panel is solid color. The white space in the lower left region is highly transparent because those parameter values
resulted in few bacteria infected; zones with intermediate levels of infection are narrow. Each panel assumes a fixed ratio of vaccine/helper output
(bVM : bMV ) and a specific number of initial vaccinations (100 or 100,000), as indicated. Black circles indicate the approximate behavior of wildtype
M13 and phagemid (a, c) and of engineered M13 and phagemid (b, d) and are placed on the panels most closely representing the empirical
relationship of bVM :bMV . The benefit of engineering a vaccine with a large reproductive excess over helper is readily evident, as is the value of
introducing larger numbers of vaccinations. Equations were those of (A1), with lethal virus omitted and all forms of vaccine-infected cells combined;
parameter values were those of Table 4 in Appendix, except for bM , bMV and bVM , which were varied and are given in the figure. The initial density of
uninfected cells was 108; vaccinated cells were introduced as HVMS at time 0
Helper-infected cells continue transmitting helper virus
and gradually spread throughout the bacterial population
(creating bacteria that cannot be infected by vaccine). In
contrast, vaccine-infected cells do not transmit until the
cell is later infected by helper. Thus early transmission
disproportionately favors the helper when the number
of manual vaccinations is low. As the number of early
manual vaccinations increases, subsequent transmission
dynamics increasingly involve the vaccine.
These analyses point to the utility of an approach that
combines engineering with dynamic analysis: engineering
is used to control the vaccine:helper output ratio from
doubly-infected cells, whereas the dynamics analyses indi-
cate what level of manual vaccination is required for a
desired final level of vaccine coverage. These analyses also
suggest that any process which increases the local density
of phages (spatial structure or increased initial vaccina-
tions) or increases co-transmission of helper and vac-
cine would improve vaccine coverage. These speculations
point toward obvious directions for future work.
Model dynamics of the full system
Many qualitative properties of the full system (vaccine,
helper, lethal virus) follow from the preceding analyses.
The vaccine can offer significant protection only to the
extent it transmits well enough to reachmuch of the popu-
lation and it is introduced enough in advance of the lethal
virus that it has time to spread and time to protect the
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cells that it reaches. Absent a sufficiently early vaccine
introduction, the lethal virus will kill most of the popula-
tion, at which point, the few vaccinated cells will dominate
the survivors (some bacteria will be resistant because
of spontaneous mutations that disable fhuA). As noted
above, there could be a long lag between acquiring the
vaccine and being protected by it (given by parameter c),
in which case, even an early vaccine introduction may not
be sufficient.
Details of the dynamics are sensitive to initial abun-
dances and to the parameters of the lethal virus (Fig. 4). A
parameter of some interest is c, the delay between infec-
tion and subsequent protection by the vaccine, which
is potentially controlled by engineering. Intuition sug-
gests that shorter delays are beneficial for protection, and
the numerical trials support this. Thus, the first three
panels of Fig. 4 differ systematically in the value of c (0.1,
0.01 or 0.001, the latter being close to the observed delay).
Dropping the conversion rate 10-fold leads to a 2.7-fold
drop in protected cells in the time frame shown; dropping
it another 10-fold leads to an additional 8.1-fold reduc-
tion in protected cells. Although perhaps not impressive
on a log scale, the differences are profound in absolute
numbers.
From panels (a)–(c), it is easily seen that helper-infected
cells (light blue) quickly become the dominant cell popu-
lation until the lethal virus ascends and kills them. They
are intrinsically doomed because the vaccine cannot infect
them. The goal, then, is to shift the dynamics toward cells
infected with the vaccine. That goal is largely achieved
in panel (d), by increasing the reproductive output 10-
fold from doubly-infected cells (bVM, bMV ). Compared to
panel (a), which otherwise used the same run conditions,
there is a substantial improvement in protection due to
replacing helper-infected cells with doubly-infected cells.
Panels (e) and (f ) invoke a 10-fold reduction in burst
size (fecundity) of the lethal virus; here cell and vac-
cine dynamics are not impacted by the lethal virus in the
time frame shown. Thus the dynamics that operate in the
absence of the lethal virus obtain in the short run for these
conditions.
Empirical dynamics of vaccine and helper
Dynamics assays in the absence of the lethal virus are
shown in Fig. 5. Both the composition and size of the
vaccine inoculum differed somewhat among trials, one
trial with a high incidence of vaccine-only infections (due
to their unexpected presence in an overnight culture of
doubly-infected cells). Even so, a comparison of the three
trials reveals the following outcomes that are qualitatively
consistent with the models. (1) All trials show the antic-
ipated rise of helper-only infections (HM), from unde-
tectable levels at 0 h to levels exceeding vaccine infections
at 3 h. The overtake of vaccine infections by helper-only
infections is predicted from the autonomy of helper virus
(Fig. 3). (2) The proportional level of vaccine coverage
increases between hour 1 and hour 3 in all trials, nearly
10-fold in the first 2 but only 3-fold in the third trial.
Other observations are at variance with the models. (3)
Vaccine infection levels at the 3-h endpoint are not obvi-
ously correlated with the double infections introduced at
time 0; the highest vaccine coverage at 3 h occurred in
the trial with the lowest input of double infections. (4)
Two trials show a 100-fold rise in doubly-infected cells
from hour 1 to hour 3. Growth of doubly-infected cells
can explain at most a 20-fold increase over two hours
(Table 3), yet infection levels in the population do not sup-
port high enough infection rates to explain the further
5-fold increase.
These discrepancies appear to be the usual, generic
quantitative nuances that arise in most empirical attempts
at a priori tests of quantitative models. They may arise
from difficulty in controlling initial conditions, or more
fundamentally, they may arise from systematic violations
of the assumptions. As a possible example of the latter
type, the cells used here may not be uniformly suscepti-
ble to infection, due to non-genetic variation in F pilus
expression. The F pilus must be extended for M13 and
phagemid infection, but the F pilus oscillates between
the extended and retracted states. If some cells are more
prone to have the pilus retracted (as suggested in previous
work, [14, 19]), they will be less susceptible to infection by
both M13 and the vaccine. Conversely, cells acquiring the
vaccine would also be prone to acquire the helper. Such
a process could explain a state in which there is both an
abundance of double infections and also an abundance of
uninfected cells. There also seems to be little that can be
done about the problem, but it is clearly a property of the
system that could be included in refined models.
Empirical dynamics of the full system
Empirical assays of the full system were undertaken to see
if vaccine performance would be as poor as expected from
the data on delayed protection (Fig. 6). A comparison of
dynamics in the presence and absence of vaccine reveals
that vaccine protection is slight, even under idealized con-
ditions favoring protection of the cell (long term growth of
vaccine and cells before introduction of the lethal virus).
From the dynamics performance in the absence of T5,
the protection should be substantial were the resistance
to take effect promptly. Thus, the system is correctable by
engineering a resistance mechanism that is much faster to
convert the cell (e.g., c = 0.1 instead of c = 0.001).
Discussion
In the treatment of chronic viral infections such as HIV,
the so-far failure of standard vaccine approaches com-
bined with the failure of drugs to cure infections (although
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Uninfected hosts  
Helper infected hosts  
Doubly infected hosts (sensitive)  
Doubly infected hosts (resistant)  
Lethal virus
Fig. 4 Numerical dynamics of lethal virus, host and two-component vaccine. Manual vaccinations were introduced as doubly-infected cells (HVMS) at
time 0. In the long term, the population comes to consist of only doubly-infected cells (HVMR , thick dark red) and lethal virus (L, purple), but the early
dynamics depend on initial conditions and the rate at which vaccine-infected cells convert from sensitive to resistance against the lethal virus (given
by c). a b c: The cases of c = 0.1, c = 0.01 and c = 0.001 are contrasted and show a large effect of delayed protection. With c = 0.001, many cells
carrying vaccine are killed because they were not yet converted to a resistant state when exposed to lethal virus. d The rates of vaccine and helper
production from doubly-infected cells are increased 10-fold over those in (a), but parameters and initial conditions are otherwise the same. The
result is a nearly 1-log increase in protected cells in the time frame shown. e f: Burst size of the lethal virus is dropped 10-fold over that in (a).
Parameters and initial conditions are otherwise the same as in (a) for panel (e), but the number of initial vaccinations (HVMS) is increased 10-fold in
(f), resulting in a 7-fold increase in protected cells. In these latter two trials, the lethal virus has effectively no effect on the bacterial dynamics in the
time frame shown. For all panels, equations used are given in (A1), parameters as in Table 4 in Appendix. Unless indicated otherwise, runs started
with 108 uninfected cells, 105 doubly-infected (sensitive), 1000 lethal virus, and a carrying capacity of 109



























































Limit of detection (helper infected)
Limit of detection (pgT infected)
Fig. 5 Empirical dynamics of the two component vaccine in absence of the lethal virus. Three replicates are shown (a)–(c), conducted at different
times but all attempting to repeat the same initial conditions. All replicates have several properties in common. (i) There is an increase in cells
infected with helper-only from undetectable at time 0 to an abundance exceeding all other types of infections at 3hr (the limit of detection is the
dashed line at 103). (ii) Cells infected with vaccine-only (pgT) increase most substantially in the first hour, then about 10-fold in the next 2 h; much of
the latter could be explained by cell growth, but the first-hour growth must be from infection. (iii) Doubly-infected cells increase slowly in the first
hour but 100-fold in the next 2 h for two of the trials. A 100-fold increase is too high to be explained by cell growth and thus must be partly from
infection. There are also obvious differences among replicates. (iv) The doubly-infected cell density at 3 h is usually around 107 despite a 10-fold
variation in the inoculum. Open symbols, which lie at the limit of detection, indicate that no bacteria were detected. Colored dashed lines indicate
that the true slope is undetermined because at least the early time point is unknown
providing ongoing HIV suppression) have led to sugges-
tions of novel interventions. One class of these interven-
tions is to infect the patient with viral agents that interfere
with the chronic infection. Proposals have ranged from
introducing viruses that kill HIV-infected cells to sub-
genomic viruses that merely suppress HIV reproduction
when both are in the same cell [2, 6–8]. Here, we used a
model system to explore yet another approach, an engi-
neered viral system to infect cells and convert them to
block infection by the chronic virus. The method does not
necessarily eradicate the chronic virus at the population
level, but it creates and dynamically maintains a subset of
cells that are protected from infection.
The specific implementation we tested was that of a
two-component ‘vaccine’ system. One viral agent is essen-
tially a gene therapy vector that infects a cell and subse-
quently prevents infection by the chronic virus. However,
by itself, this vector does not transmit between cells; it
requires a second (non-lethal virus) to mobilize it. On the
surface, the requirement of two components appears to
be dynamically unfavorable. It is indeed unfavorable, but
numerical studies indicated that certain regions of param-
eter space lead to acceptable outcomes. Those favorable
regions require engineering the reproductive properties of
vaccine and helper virus.
One of ourmain goals was to contrast models developed
from an understanding of the basic biology of the thera-
peutic agents with performance in actual implementations
by using bacteriophages. This exercise should help guide
future efforts, which are often developed from general
principles. There were in fact several challenges in imple-
mentation. First, our vaccine was slow to protect cells
against the lethal virus (phage T5). Thus, a prohibitively
long advance delivery of the two-component system was
required to achieve substantial protection in our system.
Second, reproductive rates of the vaccine and helper virus
were not quite in the optimal range for dynamical cov-
erage of the population, although engineering the helper















































Fig. 6 Dynamics with both phages. a, b Two replicates in which phage T5 was added to a culture of E. coli that had been infected and grown
overnight with vaccine/phagemid and helper (dashed lines) or added to a culture that was not exposed to phagemid or helper (solid lines). (Vaccine
and helper were added at a multiplicity of infection of 1.0 and 0.01, respectively, at initiation of the overnight culture). There is a sharp rise in T5
density after addition regardless of the presence of the vaccine (blue curves). However, cell density rebounds in the vaccine-protected population
from growth of the survivors, which are resistant. Due to the effect of helper on cell growth, a higher initial density of cells is present in the
unprotected culture than in the protected culture. c Drop in host density compared between presence and absence of the vaccine. The decline in
cell density from 2hr to 4h is only 0.75 and 1.15 logs less when the vaccine is present than when it is absent (comparing a and b)
virus greatly improved its performance. It is conceiv-
able that either or both of these imperfections could be
mitigated by further engineering.
The success of a 2-component vaccine may be improved
by increasing co-transmission of helper and vaccine to
the same host. Here, transmission was likely independent
– phagemids (vaccine) and M13 helper are produced as
separate particles and, in the mass action realm of liquid
culture, would usually encounter hosts independently of
each other. Co-transmission should improve vaccine suc-
cess because more hosts would receive the vaccine at the
same time as the helper, reducing the number of cells that
get only the vaccine or only the helper (neither of which
transmit vaccine). M13 can evolve to co-package genomes
from the same cell [20], so the system used here might
be suitable for testing the effect of co-transmission. Co-
transmission between a wild-type and a defective dengue
virus has recently been reported [21], suggesting that co-
transmission may be a feasible strategy in many systems.
A similar type of interference mechanism as here could
be achieved by engineering a single therapeutic vaccine
(instead of a two-component vaccine). A single thera-
peutic virus would have favorable dynamics over a much
larger parameter space. Yet there are likely downsides of
engineered single-component systems. A two-component
system is easier to engineer and more likely to be evo-
lutionarily stable than a single-component system. If the
single-genome vaccine is merely an attenuated (geneti-
cally weakened) version of the wild-type, there is an inher-
ent risk of the vaccine evolving back to high virulence,
much as observed with the live polio vaccine [22, 23].
Alternatively, a single-genome, ‘subunit’ vaccine that
encodes an antigenic insert may not revert to high viru-
lence (if the genomic backbone is avirulnet), but it may
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instead readily evolve to lose the insert because the sub-
unit is detrimental to spread of the genetic backbone [24].
Two-component systems should be more stable against
these unwanted outcomes. But the final choice of which
design to use may depend on details specific to the
application.
Although our system is most easily construed as a
within-host therapy against a chronic viral infection, it has
broad parallels with transmissible vaccines [6, 8, 9, 14].
In this latter context, the bacterial cells would represent
the multicellular hosts, and all within-host dynamics are
subsumed within the individual bacterial cells. The usual
interpretation of a transmissible vaccine is as a single,
self-transmissible agent, but our 2-component system has
close parallels with a proposed anti-HIV system [6, 8, 9].
Conclusions
It has been possible to develop and predict approximate
empirical behavior of a novel 2-component, transmissible
gene therapy system from first principles. The system is
intended to protect a population of host cells from eradi-
cation by a lethal virus. With only broad-scale parameter-
ization, empirical studies and mathematical models are in
broad agreement. Some dynamic anomalies suggest that
refinements of the models are justified in yielding better
agreement, but the existing agreement is encouraging if
not impressive. Despite intuition that a two-component
system is intrinsically unfavorable for population protec-
tion, the models identified parameter values where the
outcome is favorable. In one respect (relative transmission
rates of vaccine and helper), the system was engineered
toward this favorable outcome. Yet in another important
aspect, the system failed (conversion of the cell to resis-
tance was unacceptably slow). Future efforts with this sys-
tem should be directed to improving the conversion rate.
Even so, at this stage the models are successful enough
to justify using them in comparing different ‘virus wars’




Cells infected with helper produce infectious particles of
helper virus; cells doubly infected produce infectious par-
ticles of vaccine and of helper virus. The output per cell
can be obtained from the supernatant of a culture of
infected cells, but the calculation is complicated because
the cells are growing during the period of accumulation. A
pair of differential equations is an adequate model of the
process [14]:
H˙M = rMHM (1)
M˙ = bMHM (2)
where notation is as in Table 4 in Appendix. Equation 1 is
easily solved as
H(t) = HM(0)erMt , (3)
with parentheses () indicating time. Equation 2 becomes
dM = bMHM(0)erMtdt, (4)
M(t) = M(0) + HM(0)bMrM
(
erMt − 1) . (5)
When measuring bacterial and phage concentra-
tions/titers at two time points, the only unknown in Eq. (5)
is bM. For particle production from doubly-infected cells,
the equations are applied separately.
Strains andmedia
Media. Bacteria and phages were cultured in LB broth
(10g NaCl, 10g Bacto tryptone, 5g Bacto yeast extract
per liter). Plates contained LB with 15g Bacto agar per
liter.Whenmeasuring phage concentrations, soft agar (7 g
Bacto agar per liter) was used to overlay LB plates.
Bacteria and phages and phagemid. Escherichia coli
IJ338 [25] was used as the host for dynamics experiments.
Phagemid pBluescript SK(+) (ampicillin resistant), engi-
neered to carry a targetron gene programmed to disrupt
E. coli gene fhuA, was used as the vector for delivery of
the vaccine (named pgT, see below). The wild-type M13
phage was JB5 [25], an f1 (M13) with a kanamycin resis-
tance gene cloned into the intergenic region. (Wild-type
phages f1 and M13 are nearly identical in sequence and
are considered equivalent.) The commercial helper phage
M13KO7 (also Kn-resistant) was used as an M13 engi-
neered to overproduce phagemid. Bacteriophage T5 was
the lethal virus.
Targetron cloning
The LtrB intron donor plasmid pACD4-G [16] was mod-
ified to target the E. coli fhuA gene. Predicted fhuA
insertion sites and gBlock designs for retargeting the
LtrB intron were generated using TargeTronics, LLC
(www.targetrons.com). The predicted site with the high-
est score (LtrB insertion occurring between base-pairs
1446|1447 on fhuA) was selected for TargeTron repro-
gramming (nucleotide sequence coordinates after LtrB
insertion into the fhuA gene: 5’-TATGTTCAGGATCAGG
CGCAGTGGGATAAA- LtrB -GTGCTGGTTACGCTT).
The gBlock fragment (obtained from IDT) used to modify
the LtrB intron in pACD4-G was PCR amplified, puri-
fied in a 0.8 % agarose gel, digested with HindIII and
BsrGI, and swapped with the corresponding fragment
in the pACD4-G donor plasmid (named pACD4-fhuA).
Modification was confirmed using Sanger sequencing.
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Essential targetron genes (LtrB intron and LtrA) were
cloned into pBluescript(SK+) to generate the pgT con-
struct by digesting pACD4-fhuA with EcoO109I and
HindIII, purifying in a 0.8 % agarose gel, and swapping
with the corresponding fragment on pBluescript(SK+).
pgT was transformed into IJ338 and targetron insertion
into the bacterial fhuA gene was confirmed via PCR
amplicon size.
To generate the pgT phage stocks, pgT-infected IJ338
was grown in LB + Amp culture, infected with M13KO7
helper phage, and plated on LB agar plates with Kn and
Amp to select for colonies doubly infected with pgT and
M13KO7. Colonies were picked and grown overnight in
LB with Amp and Kn. The overnight culture was incu-
bated at 65 °C for 60 minutes to kill bacteria, spun down
and the supernatant containing pgT and M13KO7 phage
particles was collected.
Dynamics assays
Cultures were incubated at 37 °C. Dynamics were car-
ried out in 10 mL volumes of LB broth. Frozen stocks of
bacteria (IJ338) weremade by concentrating exponentially
growing cells (grown in LB broth), aliquoting and freezing
in 20 % LB glycerol. Frozen stocks were stored at -80°C.
Cells were thawed just before use and added to 10 mL LB
broth in 125 mL flasks and grown with aeration (170 rpm)
for 60 min to a density of ∼ 108 cells/ml, at which point
T5 phage or pgT was added, depending on the dynam-
ics being tested. The volumes were diluted 10X when
cell densities were high enough to inhibit further host
growth.
Densities of T5 were measured as plaque-forming units
in soft agar on a lawn of sensitive bacteria. Densities
of phagemid and M13 were determined by an overlay
method [25] as follows. Sensitive cells were mixed in soft
agar and spread on LB agar plates to create a lawn. After
this layer set, phage suspended in 2-4 μL were streaked
on top of the lawn and allowed to dry. A second, empty
layer of soft agar was poured and allowed to set (this layer
prevents cells from being spread when the third layer is
poured). The plate was incubated for 1–2 h at 37 °C to
allow infection. Antibiotic corresponding to the resistance
carried by f1 was then mixed with soft agar and over-
lain on top so that only cells infected with f1 would form
colonies.
Testing for incidence of T5 resistance
In both assays, a suspension of pgT particles was added at
an MOI of 1.0 to a culture of IJ338 that had been grown
for 1 h. IPTG was added to 1 mM to induce targetron
expression. In one assay, cells were plated separately on
ampicillin and on a high density of T5 at 1, 4 and 8 h. 100-
fold dilutions were made every 2-3 h to prevent resources
from limiting host growth. In the other assay, T5 was
added to the culture, grown for 3–4 h, and the culture
plated for surviving cells.
Dynamics with both phages
A suspension of the vaccine (pgT) was added to a culture
of cells grown for 1 h to a density of∼ 108 phage/ml; IPTG
was present (1 mM) to induce expression of the targetron
gene. The culture was grown for 3 h, 7 h, or overnight
(minimally 14 h). For overnight growth, the culture was
diluted 10X at the start, then diluted 10X the following
morning and grown for an additional hour before addi-
tion of T5. Phage T5 was added at a density of ∼ 106
phage/ml. Bacteriophage samples were taken at each hour
and cell densities were measured via plating on agar plates
and incubating overnight at 37 °C. Samples of pgT were
purified by incubating the sample at 65 °C for 60 minutes
to kill bacteria and T5, centrifuging debris and collect-
ing the supernatant. T5 samples were purified by mixing
sample with chloroform to kill phagemid, M13 and bacte-
ria, centrifuging and collecting supernatant. pgT numbers
were measured as described above. T5 concentrations
were measured by counting plaques on a lawn of sensitive
cells. To determine the fraction of cells infected with pgT
at each time point, colonies grown in the absence of drug
were stabbed onto new agar plates containing ampicillin.
Dynamics with T5 in the absence of vaccine protection
T5 was added to a growing culture of cells at a density of
∼ 2 × 109 phage/ml. Each hour, phage were collected as
described above and cells were plated on LB agar plates
for density. T5 phage concentration was measured by
counting plaques on a lawn of sensitive IJ338.
Dynamics of the two component vaccine in the absence of
lethal virus
IJ338 was infected with a suspension of pgT plusM13KO7
and plated on LB containing kanamycin and ampicillin
to select bacteria infected with both phage-types. 10-15
colonies were picked and grown in LB containing Amp
and Kn overnight. The following day, IJ338 was grown for
1 h to a concentration between 5×107 and 1×108 cells/ml.
At 1 h, the culture of doubly-infected cells was spun down
at 2000 rpm for 2 minutes, resuspended in LB, and added
to the IJ338 culture at a concentration between 5 × 104
and 8 × 105 cells/ml. Cell densities were measured at 0,
1, and 3 h via plating. Total density was determined by
plating on LB agar plates while densities of pgT-infected
and M13KO7-infected bacteria were measured by plating
on LB agar plates containing Amp and Kn respectively.
To determine the fraction of cells doubly infected (with
phagemid and helper phage) or singly infected (phagemid
alone or helper phage alone), colonies from the kanamycin
and ampicillin plates were stabbed onto separate plates
with ampicillin and kanamycin respectively.
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Appendix: Equations of dynamics
We use ordinary differential equations to model phage
dynamics, as has been standard for many decades [18].
A superior dot over a variable indicates a derivative with
respect to time. Nine variables and 14 parameters specify
behavior of the cells and viruses in our system. Infec-
tion rates are assumed to follow mass action, the number
of host cells infected being the product of host density,
viral (or vaccine) density, and an adsorption rate parame-
ter (k). The lethal virus releases b viral progeny τ minutes
after infection (a parenthetical t − τ indicates the value τ
minutes in the past). Lethal infections have such a short
lifespan that the equation is omitted for cells infected with
the lethal virus. As our model assumes a closed system,
it includes a logistic growth function (G) to limit host
density to a carrying capacity. Although our helper virus
(M13) is known to adversely affect maximal density to a
small degree [14], we use a common carrying capacity for
uninfected cells and helper-infected cells.
V˙ = bV (HVMS + HVMR) − kVVHu
M˙ = bMHM + bMV (HVMS + HVMR)
− kMM(Hu + HVS + HVR)
L˙ = bLkLL(t − τ) [Hu(t − τ) + HM(t − τ)
+ HVS(t − τ) + HVMS(t − τ)]
− kLL(Hu + HVS + HM + HVMS)
(A1)
Table 4 Model variables and parameters
Notation Description Values
Variables
V Density of vaccine (free particles)
M Density of helper virus (free particles)
L Density of lethal virus (free particles)
Hu Density of uninfected cells
HVS Density of cells infected with vaccine but still sensitive to lethal virus
HVR Density of cells infected with vaccine and resistant to lethal virus
HM Density of cells infected with helper
HVMS Density of cells infected with vaccine and helper but still sensitive to lethal virus
HVMR Density of cells infected with vaccine and helper and resistant to lethal virus
Functions
G Density-adjusted growth factor for all cells [= 1 − (Hu + HM + HVS + HVR + HVMS + HVMR)/C]
Parameters
kV Adsorption rate of vaccine to uninfected cells (mL/min) 5 × 10−9
kM Adsorption rate of helper virus to all cells that it infects (mL/min) 5 × 10−9
kL Adsorption rate of lethal virus to all cells that it infects cells (mL/min) 5 × 10−10
ru Intrinsic growth rate of uninfected cells (/min) 0.033
rV Intrinsic growth rate of vaccine-infected cells (/min) 0.033
rM Intrinsic growth rate of helper-infected cells (/min) 0.03
rVM Intrinsic growth rate of cells infected with vaccine and helper (/min) 0.025
c Rate of conversion to T5 resistance by vaccine-infected cells (/min) 0.1, 0.001
bM Rate at which helper-infected cells produce helper (/min) 0.5
bVM Rate at which vaccine-infected, helper-infected cells produce vaccine (/min) 0.7
bMV Rate at which vaccine-infected, helper-infected cells produce helper (/min) 0.006
bL Burst size of a cell infected with lethal virus 200
τ Time after infection that a cell infected with the lethal virus dies (min) 30
C Carrying capacity of environment 1 × 109
Values of bV , bVM , and bMV and rM and rVM , are for helper M13KO7 and are per minute; these and corresponding values for wild-type M13 are given per hour in Table 2. The
value of c = 0.001 is in reasonable agreement with the data; the value of c = 0.1 is used to show the possible benefit of engineering this parameter value
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H˙u = ruGHu − kVVHu − kMMHu − kLLHu
H˙VS = −cHVS − kMMHVS − kLLHVS
+ kVVHu + rV GHVS
H˙VR = cHVS − kMMHVR + rV GHVR
H˙M = −kLLHM + kMMHu + rM GHM
H˙VMS = −cHVMS − kLLHVMS + kMMHVS + rVM GHVMS
H˙VMR = cHVMS + kMMHVR + rVM GHVMR
Additional files
Additional file 1: Original data file used to generate estimates in Table 2.
Additional file 2: Mathematica file used to generate Fig. 4d. Changes in
parameters and initial densities are needed to generate the other panels.
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